home All News open_in_new Full Article

Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)

Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Dosing Plan to Initiate Clinical Studies in at Least Two Autoimmune Diseases in the Second Half of This Year Aurinia to Host Conference Call Today, June 30, at 8:30 a.m. ET ROCKVILLE, Md. & EDMONTON, Alberta — Aurinia […]


today 69 h. ago attach_file Other

attach_file Technology
attach_file Culture
attach_file Other
attach_file Other
attach_file Other
attach_file Economics
attach_file Other
attach_file Economics
attach_file Events
attach_file Transport
attach_file Culture
attach_file Events
attach_file Economics
attach_file Other
attach_file Other
attach_file Society
attach_file Culture
attach_file Other
attach_file Events
attach_file Sport


ID: 3480004320
Add Watch Country

arrow_drop_down